论文部分内容阅读
应用放射自显术对10例急性白血病患者,3例慢粒白血病患者的骨髓标本进行了~3H—TdR(氚标记胸腺嘧啶核苷)体外标记测定(简称氚标记指数测定),并以11例骨髓象基本正常(无白血病或其他恶性病患者)的骨髓作为对照。部分白血病患者在治疗过程中进行了两次或多次标记测定。利用~3H—TdR 能特异地掺入 DNA 分子内,使处于 DNA 合成期(即 S 期)的细胞受到同位素标记。计算有核细胞中标记细胞的百分率(LI%),作为骨髓增殖细胞群大小的指数。结果表明,急性白血病患者在治疗前及未缓解者的 LI 平均值(1),明显小于对照(2),完全缓解者的 LI(3)亦明显大于(1)甚至接近(2)的水平,而治疗前和未缓解的慢粒患者的 LI(4)则介于(1)与(2)之间。此法不但有助于早期探测白血病患者的病情变化,对化疗的反应及予测予后,因而在临床治疗上具有实际意义,并且可提供人类白血病细胞的特定动力学参数。
Using autoradiography in 10 cases of acute leukemia, 3 cases of chronic myeloid leukemia patients were measured 3H-TdR (tritiated thymidine) in vitro labeling assay (tritium labeling index determination), and 11 cases Bone marrow as a normal (no leukemia or other malignant patients) bone marrow as a control. Some leukemia patients underwent two or more marker determinations during treatment. The use of ~ 3H-TdR can be specifically incorporated into DNA molecules, so that the cells in the DNA synthesis phase (ie S phase) are isotopically labeled. The percentage of labeled cells in nucleated cells (LI%) was calculated as an index of the myeloid proliferating cell population size. The results showed that the mean LI of patients with acute leukemia before treatment and without remission (1) was significantly lower than that of control (2), and LI (3) of patients with complete remission was significantly higher than (1) or even close to (2) However, LI (4) in pretreatment and non-mitochondrial responses was between (1) and (2). This method will not only help early detection of leukemia changes in patients with response to chemotherapy and to be given after the test, which has practical significance in clinical treatment, and can provide human leukemia cells specific kinetic parameters.